Table 2.

Significant survival benefit of included trials

Drug type	Randomized studies (n = 29)	Non-randomized studies (n = 104)
		all non-randomized trials	trials reporting adjusted survival analysis (n = 49)	trials reporting unadjusted survival analysis (n = 55)
All drugs	2/29 (7%)	32/104 (31%)	23/49 (47%)	9/55 (16%)
Hydroxychloroquine+ azithromycin (n = 27)	0/4 (0%)	6/23 (26%)	5/16 (31%)	1/7 (14%)
Hydroxychloroquine (n = 22)	0/7 (0%)	5/15 (33%)	4/10 (40%)	1/5 (20%)
IL-6 inhibitors (n = 36)	0/3 (0%)	13/33 (39%)	8/10 (80%)	5/23 (22%)
Corticosteroids (n = 26)	2/6 (33%)	4/20 (20%)	3/8 (37%)	1/12 (8%)
Convalescent plasma (n = 10)	0/3 (0%)	1/7 (14%)	1/3 (33%)	0/4 (0%)
Remdesivir (n = 5)	0/3 (0%)	2/2 (100%)	1/1 (100%)	1/1 (100%)
Other (n = 7)	0/3 (0%)	1/3 (33%)	1/1 (100%)	0/3 (0%)